SM
Therapeutic Areas
Rapport Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| RAP-219 | Drug-Resistant Focal Epilepsy | Phase 1b/2a |
| Undisclosed GABA-A RAP Program | Anxiety Disorders | Discovery |
| Undisclosed AMPA RAP Program | Cognitive Impairment | Discovery |
Leadership Team at Rapport Therapeutics
A(
Abraham (Avri) C. C. C. C. C.
Chief Executive Officer & Director
DB
David Bredt
Chief Scientific Officer & Head of R&D
WD
Wendy DiCicco
Chief Operating Officer & Chief Financial Officer
K(
Katherine (Kate) Tenaerts
Chief Business Officer
RM
Ramy Mahmoud
Chief Medical Officer
CR
Carlo Rizzuto
Chairman of the Board, Partner at Third Rock Ventures
KS
Kevin Starr
Board Director, Partner at Third Rock Ventures
AC
Abbie Celniker
Board Director, Partner at Third Rock Ventures
LR
Liam Ratcliffe
Board Director, Managing Director at New Enterprise Associates (NEA)
KY
Krishna Yeshwant
Board Director, General Partner at Google Ventures (GV)